Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TVI-Brain-1 in Newly Diagnosed MGMT Unmethylated Glioblastoma
NCT05685004Phase 3Active, not recruiting
- Sponsor
- TVAX Biomedical
- Start
- Dec 2023
- Primary completion
- Nov 2030
- Modality
- Prophylactic Vaccines, Cancer Vaccines, Native Immune Cells
- Countries
- 1
01
Overview
Phase 3, randomised trial in glioblastoma multiforme (GBM) comparing Standard of Care with Interventional TVI-Brain-1 (2 arms). Primary endpoint: Overall Survival at 24 months. Started Dec 2023; status: active, not recruiting.
02
Drugs
TVI-Brain 1
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT05685004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05685004.